EE447 Economic Evaluation of Envonalkib, Iruplinalkib, and Critizonib in the Treatment of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer in China
Abstract
Authors
L Yuhang H Zhang X Yeyou R Xiong Y Liu Z Qiu W Hong